Milestone Pharma reports Q4 net loss of $13.6M; on track to resubmit NDA for etripamil in PSVT early Q2 2024

Milestone Pharmaceuticals Inc.

Net loss of $13.6M in Q4 2023, full year net loss $59.7M; Q4 revenue was $0 (vs $3.5M in Q4 2022).
Cash and equivalents $66M as of Dec 31, 2023; March 2024 offering raised ~$32.4M net, extending cash runway into 2026.
Plans to resubmit NDA for etripamil in PSVT early Q2 2024 after Type A meeting with FDA resolved RTF items.
FDA reiterated guidance for AFib-RVR Phase 3 pathway contingent on PSVT NDA approval; End of Phase 2 meeting expected mid-2024.
R&D expense fell to $5.5M in Q4 (vs $10.6M) as Phase 3 studies completed; commercial expense rose to $5.0M (vs $2.6M) for launch prep.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Milestone Pharmaceuticals Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 21, 2024, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

Milestone Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-036941

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.